After weight loss, Alzheimer’s may be next frontier for drugs like Ozempic
By Natalie Grover LONDON (Reuters) – Diabetes drugs that also promote weight loss such as Novo Nordisk’s Ozempic, becoming a darling of celebrities and investors, are being studied to tackle some of the most difficult-to-treat brain disorders, including Alzheimer’s disease. Diabetes regimens, from Ozempic to old mainstays like insulin and metformin, appear to address several…
